1. Home
  2. PXED vs OBX Comparison

PXED vs OBX Comparison

Compare PXED & OBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Phoenix Education Partners Inc.

PXED

Phoenix Education Partners Inc.

HOLD

Current Price

$23.83

Market Cap

980.1M

Sector

Real Estate

ML Signal

HOLD

Logo Obsidian Therapeutics Inc. Common Stock

OBX

Obsidian Therapeutics Inc. Common Stock

N/A

Current Price

$14.33

Market Cap

839.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PXED
OBX
Founded
1976
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
980.1M
839.5M
IPO Year
2025
2026

Fundamental Metrics

Financial Performance
Metric
PXED
OBX
Price
$23.83
$14.33
Analyst Decision
Buy
Strong Buy
Analyst Count
7
5
Target Price
★ $40.75
$39.00
AVG Volume (30 Days)
78.4K
★ 395.2K
Earning Date
11-03-2026
11-13-2026
Dividend Yield
★ 3.53%
N/A
EPS Growth
N/A
N/A
EPS
★ 1.69
N/A
Revenue
N/A
N/A
Revenue This Year
$1.56
N/A
Revenue Next Year
$3.25
N/A
P/E Ratio
$14.07
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$23.42
$11.52
52 Week High
$38.19
$39.00

Technical Indicators

Market Signals
Indicator
PXED
OBX
Relative Strength Index (RSI) 31.92 48.90
Support Level N/A $12.16
Resistance Level $30.79 $18.21
Average True Range (ATR) 0.86 1.10
MACD -0.05 0.34
Stochastic Oscillator 10.16 87.99

Price Performance

Historical Comparison
PXED
OBX

About PXED Phoenix Education Partners Inc.

Phoenix Education Partners Inc. is a mission-driven organization operating at the forefront of the rapidly evolving post-secondary education market. it is an online education provider and a pioneer in its field. The company benefits from the dynamic interplay between technological innovation, education, employment, and economic trends. It is focused on delivering personalized, career-relevant, and affordable education to its students through its flexible learning model, skills-aligned curriculum, and accessible tuition costs.

About OBX Obsidian Therapeutics Inc. Common Stock

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.

Share on Social Networks: